• Dépistage, diagnostic, pronostic

  • Essais de technologies et de biomarqueurs dans un contexte clinique

  • Voies aérodigestives supérieures

Tumor budding and lymphovascular invasion as prognostic factors in p16-positive oropharyngeal squamous cell carcinomas

Menée à partir de l'analyse de lames histologiques colorées à l'hématoxyline et à l'éosine puis numérisées, cette étude met en évidence une association entre la présence d'un envahissement lymphovasculaire ou d'un bourgeonnement tumoral et le pronostic chez les patients atteints d'un carcinome épidermoïde de l'oropharynx exprimant la protéine p16

Background : We aimed to validate the prognostic significance of tumor budding (TB) in p16-positive oropharyngeal squamous cell carcinomas (OPSCC).

Methods : We analyzed digitized H&E-stained slides from a multicenter cohort of five large university centers consisting of n = 275 cases of p16-positive OPSCC. We evaluated TB along with other histological parameters (morphology, tumor-stroma-ratio, lymphovascular invasion (LVI), perineural invasion) and calculated survival outcomes using both univariate and multivariate analyses.

Results : TB was identified as an independent prognostic parameter, with TB-high cases showing inferior outcomes in univariate (HR: 3.08, 95%-CI: 1.71–5.54) and multivariate analyses (HR: 4.03, 95%-CI: 1.65–9.83). Similarly, LVI remained an independent prognostic factor (HR: 3.00, 95%-CI: 1.22–7.38). A combined classification including TB and LVI stratified cases into low-, intermediate- and high-risk categories. We could not detect correlations between TB and the number of lymph node metastases or between TB and an extracapsular extension of lymph node metastases.

Conclusions : In addition to LVI, we could identify TB as an independent prognostic factor in p16-positive OPSCC in this multicenter study cohort. Thus, evaluating TB along with LVI in a combined scheme for prognostication might help to establish a more personalized treatment regimen for patients with p16-positive OPSCC.

British Journal of Cancer , article en libre accès, 2024

Voir le bulletin